Following a routing challenge raised by the company, regarding the Topic Selection Oversight Panel’s decision to route maralixibat as a Single Technology Appraisal instead of as a Highly Specialised Technology, the start of this appraisal is therefore delayed. The timelines for this appraisal will be confirmed once NICE has considered this challenge.